Addressing the root cause of T2D and obesity in the duodenum

T2D and obesity are driven by diet-induced gut dysfunction–a target at the core of the T2D and obesity pandemic

Tackling gut dysfunction at an early stage of disease might therefore be a promising treatment option to fight obesity and the resulting risks and complications.

Tschop and colleagues

REVITA IS DESIGNED FOR BROAD LARGE POPULATION ACCESSIBILITY

The Revita system comprises the Revita console that houses our proprietary technology and software and a single-use Revita catheter and single-use lineset.

< 1 hour procedure time
< 5 cases for proficiency

Straightforward procedure for patients and endoscopy teams
Designed to enable durable and repeatable metabolic improvement
Device and procedure optimized over 300 human procedures
80+ patents issued worldwide covering methods, systems, and devices

Revita is now available in Germany

Revita in Germany

REVITA DEVELOPMENT PIPELINE IN T2D AND OBESITY

*Revita has been granted Breakthrough Device designation to improve glycemic control and eliminate insulin needs in T2D patients inadequately controlled on long-acting insulin; and CE mark obtained from EU and UK in 2016

Addressing the root cause of T2D and obesity in the duodenum

T2D and obesity are driven by diet-induced gut dysfunction–a target at the core of the T2D and obesity pandemic

REVITA IS DESIGNED FOR BROAD LARGE POPULATION ACCESSIBILITY

REVITA IS DESIGNED FOR BROAD LARGE POPULATION ACCESSIBILITY

Revita is now available in Germany

REVITA DEVELOPMENT PIPELINE IN T2D AND OBESITY

You are now leaving the Fractyl.com website

YOU ARE ABOUT TO LEAVE A WEBSITE WHERE A MEDICAL DEVICE IS AVAILABLE FOR INVESTIGATIONAL USE UNDER THE OVERSIGHT OF THE UNITED STATES FOOD & DRUG ADMINISTRATION (FDA). THE PRODUCT IS INTENDED SOLELY FOR INVESTIGATIONAL PURPOSES AND HAS NOT YET RECEIVED FULL REGULATORY APPROVAL.